Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.

Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M.

PLoS One. 2011 Jan 31;6(1):e14640. doi: 10.1371/journal.pone.0014640.

2.

A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I.

Cancer Res. 2010 Feb 1;70(3):1082-9. doi: 10.1158/0008-5472.CAN-09-2405. Epub 2010 Jan 26.

3.

Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy.

Phung YT, Barbone D, Broaddus VC, Ho M.

J Cancer. 2011;2:507-14. Epub 2011 Oct 13.

4.

Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.

Anticancer Res. 2012 Dec;32(12):5151-8.

PMID:
23225411
5.

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.

Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2.

6.

New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.

Zhang YF, Phung Y, Gao W, Kawa S, Hassan R, Pastan I, Ho M.

Sci Rep. 2015 May 21;5:9928. doi: 10.1038/srep09928.

7.

The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.

Liu XF, FitzGerald DJ, Pastan I.

Cancer Res. 2013 Apr 1;73(7):2281-8. doi: 10.1158/0008-5472.CAN-12-3436. Epub 2013 Jan 24.

8.
9.

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.

Clin Cancer Res. 2007 Sep 1;13(17):5144-9.

10.

Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.

Kim H, Gao W, Ho M.

PLoS One. 2013 Nov 15;8(11):e81919. doi: 10.1371/journal.pone.0081919. eCollection 2013.

11.

Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids.

Lei H, Hofferberth SC, Liu R, Colby A, Tevis KM, Catalano P, Grinstaff MW, Colson YL.

J Thorac Cardiovasc Surg. 2015 May;149(5):1417-24; discussion 1424-25.e1. doi: 10.1016/j.jtcvs.2015.02.020. Epub 2015 Feb 14.

PMID:
25841659
12.

Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid model.

Kim H, Phung Y, Ho M.

PLoS One. 2012;7(6):e39556. doi: 10.1371/journal.pone.0039556. Epub 2012 Jun 21.

13.

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang QC, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.

Bioconjug Chem. 2007 May-Jun;18(3):773-84. Epub 2007 Mar 9.

PMID:
17346030
15.

Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.

Liu XF, Xiang L, FitzGerald DJ, Pastan I.

Mol Cancer Ther. 2014 Jan;13(1):82-9. doi: 10.1158/1535-7163.MCT-13-0726. Epub 2013 Oct 21.

16.

Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.

Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I.

Cancer Res. 2011 Sep 1;71(17):5915-22. doi: 10.1158/0008-5472.CAN-11-0466. Epub 2011 Jul 20.

17.

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.

Mol Cancer Ther. 2013 Jan;12(1):48-57. doi: 10.1158/1535-7163.MCT-12-0336. Epub 2012 Nov 6.

18.

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.

19.

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.

20.

Diversity of cell-mediated adhesions in breast cancer spheroids.

Ivascu A, Kubbies M.

Int J Oncol. 2007 Dec;31(6):1403-13.

PMID:
17982667

Supplemental Content

Support Center